Accéder au contenu
Merck

Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.

Antimicrobial agents and chemotherapy (2009-08-19)
Andrea Von Groll, Anandi Martin, Pontus Jureen, Sven Hoffner, Peter Vandamme, Françoise Portaels, Juan Carlos Palomino, Pedro Almeida da Silva
RÉSUMÉ

This study evaluated cross-resistance of Mycobacterium tuberculosis strains to ofloxacin, moxifloxacin, and gatifloxacin and investigated the presence of mutations in gyrA and gyrB. Fluoroquinolone susceptibilities were determined for 41 M. tuberculosis strains by the proportion method on 7H11, and MICs were determined by the resazurin microtiter assay. Forty strains shared the same resistance results for the three fluoroquinolones. However, one strain, with an Asn-533 --> Thr mutation in gyrB, was susceptible to ofloxacin but resistant to moxifloxacin and gatifloxacin.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ofloxacin, fluoroquinolone antibiotic
Supelco
Ofloxacin, VETRANAL®, analytical standard